Exact Mass: 694.3762

Exact Mass Matches: 694.3762

Found 284 metabolites which its exact mass value is equals to given mass value 694.3762, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Elatine

Aconitane-4-methanol, 20-ethyl-7,8-(methylenebis(oxy))-, 1,6,14,16-tetramethoxy-2-(3-methyl-2,5-dioxo-1-pyrrolidinyl)benzoate(ester), (1-alpha,6-beta,14-alpha,16-beta)-

C38H50N2O10 (694.3465)


A diterpene alkaloid isolated from Delphinium shawurense.

   

Atractyloside E

Atractyloside E

C32H54O16 (694.3412)


   

Capsoside A

2-[(3E)-Hex-3-enoyloxy]-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl dodecanoic acid

C33H58O15 (694.3776)


Constituent of the fruit of Capsicum annuum variety acuminatum. Capsoside A is found in many foods, some of which are italian sweet red pepper, orange bell pepper, green bell pepper, and herbs and spices. Capsoside A is found in fruits. Capsoside A is a constituent of the fruit of Capsicum annuum var. acuminatum.

   

Nemifitide

2-[({1-[2-amino-3-(4-fluorophenyl)propanoyl]-4-hydroxypyrrolidin-2-yl}(hydroxy)methylidene)amino]-5-carbamimidamido-N-({[1-(C-hydroxycarbonimidoyl)-2-(1H-indol-3-yl)ethyl]-C-hydroxycarbonimidoyl}methyl)pentanimidate

C33H43FN10O6 (694.3351)


   

PA(13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/13:0)

[(2R)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/13:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/13:0)

[(2R)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/13:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/13:0)

[(2R)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/13:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/13:0)

[(2R)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/13:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

[(2R)-2-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/13:0)

[(2R)-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/13:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(a-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/a-13:0)

[(2R)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/a-13:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(a-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/a-13:0)

[(2R)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/a-13:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(a-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/a-13:0)

[(2R)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/a-13:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(a-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/a-13:0)

[(2R)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/a-13:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

[(2R)-3-[(10-methyldodecanoyl)oxy]-2-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(a-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/a-13:0)

[(2R)-2-[(10-methyldodecanoyl)oxy]-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/a-13:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(i-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-13:0)

[(2R)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-13:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(i-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-13:0)

[(2R)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-13:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(i-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-13:0)

[(2R)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-13:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(i-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-13:0)

[(2R)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-13:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

[(2R)-3-[(11-methyldodecanoyl)oxy]-2-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(i-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-13:0)

[(2R)-2-[(11-methyldodecanoyl)oxy]-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C38H63O9P (694.4209)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-13:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   

(4,4-Dihydroxy-2,2-dimethyl-3,3,6,6-tetraoxo[1,1-bi-1,4-cyclohexadien-1-yl]-5,5-diyl)bis(2,6-dimethyl-2-hexene-6,1-diyl) ester 2-methyl-butanoic acid

(4,4-Dihydroxy-2,2-dimethyl-3,3,6,6-tetraoxo[1,1-bi-1,4-cyclohexadien-1-yl]-5,5-diyl)bis(2,6-dimethyl-2-hexene-6,1-diyl) ester 2-methyl-butanoic acid

C40H54O10 (694.3717)


   

SCHEMBL17305089

SCHEMBL17305089

C36H54O13 (694.3564)


   

[S-[R*,R*-(E,E)]]-(4,4-Dihydroxy-2,2-dimethyl-3,3,6,6-tetraoxo[bi-1,4-cyclohexadien-1-yl]-5,5-diyl)bis(2,6-dimethyl-2-hexene-6,1-diyl) ester 3-methyl-butanoic acid

[S-[R*,R*-(E,E)]]-(4,4-Dihydroxy-2,2-dimethyl-3,3,6,6-tetraoxo[bi-1,4-cyclohexadien-1-yl]-5,5-diyl)bis(2,6-dimethyl-2-hexene-6,1-diyl) ester 3-methyl-butanoic acid

C40H54O10 (694.3717)


   

Khekadaengoside F

Khekadaengoside F

C36H54O13 (694.3564)


   
   

periforoside I

periforoside I

C36H54O13 (694.3564)


   

N1,N4,N12-tris(dihydrocaffeoyl)spermine

N1,N4,N12-tris(dihydrocaffeoyl)spermine

C37H50N4O9 (694.3578)


   

Esculentoside D

Esculentoside D

C37H58O12 (694.3928)


   
   

2-acetoxy-15-bromo-7,16-dihydroxy-3-palmitoxy-neoparguera-4(19),9(11)-diene

2-acetoxy-15-bromo-7,16-dihydroxy-3-palmitoxy-neoparguera-4(19),9(11)-diene

C38H63BrO6 (694.3808)


   

12-O-acetylpergularin 3-O-beta-oleandropyranosyl-(1->4)-beta-oleandropyranoside

12-O-acetylpergularin 3-O-beta-oleandropyranosyl-(1->4)-beta-oleandropyranoside

C37H58O12 (694.3928)


   

5alpha-4,5-dihydroscillaren A

5alpha-4,5-dihydroscillaren A

C36H54O13 (694.3564)


   
   

bieremoligularolide

bieremoligularolide

C40H54O10 (694.3717)


   
   

Cimidahuside C

Cimidahuside C

C37H58O12 (694.3928)


   

2alpha,3beta,19alpha-trihydroxyurs-12-en-24,28-dioic acid-28-O-(3-O-methyl-beta-D-glucopyranosyl) ester

2alpha,3beta,19alpha-trihydroxyurs-12-en-24,28-dioic acid-28-O-(3-O-methyl-beta-D-glucopyranosyl) ester

C37H58O12 (694.3928)


   

grifolinone B

grifolinone B

C44H54O7 (694.3869)


   

(4,4-Dihydroxy-2,2-dimethyl-3,3,6,6-tetraoxo[1,1-bi-1,4-cyclohexadien-1-yl]-5,5-diyl)bis(2,6-dimethyl-2-hexene-6,1-diyl) ester 2-methyl-butanoic acid

(4,4-Dihydroxy-2,2-dimethyl-3,3,6,6-tetraoxo[1,1-bi-1,4-cyclohexadien-1-yl]-5,5-diyl)bis(2,6-dimethyl-2-hexene-6,1-diyl) ester 2-methyl-butanoic acid

C40H54O10 (694.3717)


   

(2R,3R,4R,5R,7S,8S,9S,11E,13S,15R)-2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one-7,8,9-triacetate-2,5-bis(2-methylbutyrate)|2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one 7,8,9-triacetate 2,5-bis(2-methylbutyrate)

(2R,3R,4R,5R,7S,8S,9S,11E,13S,15R)-2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one-7,8,9-triacetate-2,5-bis(2-methylbutyrate)|2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one 7,8,9-triacetate 2,5-bis(2-methylbutyrate)

C36H54O13 (694.3564)


   
   
   

24-O-beta-D-Glucopyranoside,6-sulfate-Cholestane-3,6,8,15,24-pentol

24-O-beta-D-Glucopyranoside,6-sulfate-Cholestane-3,6,8,15,24-pentol

C33H58O13S (694.3598)


   

sulfangolid B ammonium salt

sulfangolid B ammonium salt

C36H54O11S (694.3387)


   

(1R)-1,4-epoxy-11alpha,22alpha-dihydroxy-3,4-seco-lup-20(30)-ene-3,28-dioic acid 3-methyl ester 28-O-beta-D-glucopyranoside|acanthosessilioside C

(1R)-1,4-epoxy-11alpha,22alpha-dihydroxy-3,4-seco-lup-20(30)-ene-3,28-dioic acid 3-methyl ester 28-O-beta-D-glucopyranoside|acanthosessilioside C

C37H58O12 (694.3928)


   

19alpha-hydroxy-2,3-secours-12-en-2,3,28-trioic acid 3-methyl-28-O-beta-D-glucopyranosyl ester|potentillanoside E

19alpha-hydroxy-2,3-secours-12-en-2,3,28-trioic acid 3-methyl-28-O-beta-D-glucopyranosyl ester|potentillanoside E

C37H58O12 (694.3928)


   

2alpha,3beta,19alpha-trihydroxyurs-12-en-24,28-dioic acid 24-methyl ester 28-O-beta-D-glucopyranosyl ester

2alpha,3beta,19alpha-trihydroxyurs-12-en-24,28-dioic acid 24-methyl ester 28-O-beta-D-glucopyranosyl ester

C37H58O12 (694.3928)


   
   

17alpha-digitoxigenin beta-D-glucos-3-ulosyl-(1->4)-alpha-L-thevetoside

17alpha-digitoxigenin beta-D-glucos-3-ulosyl-(1->4)-alpha-L-thevetoside

C36H54O13 (694.3564)


   
   

24-hydroxy-15,16-seco-cycloartane 3-O-beta-D-xylopyranoside

24-hydroxy-15,16-seco-cycloartane 3-O-beta-D-xylopyranoside

C37H58O12 (694.3928)


   

18-O-beta-D-glucopyranosyl-18S-hydroxyneodihydroprotolichesterinate 21-O-beta-D-glucopyranoside

18-O-beta-D-glucopyranosyl-18S-hydroxyneodihydroprotolichesterinate 21-O-beta-D-glucopyranoside

C33H58O15 (694.3776)


   

16-oxoalbatrellin|grifolinone B

16-oxoalbatrellin|grifolinone B

C44H54O7 (694.3869)


   

2-O-beta-D-glucopyranosylcucurbitacin K,J|cucurbitacin J 2-O-beta-D-glucopyranoside|cucurbitacin J 2-O-beta-glucopyranoside|cucurbitacin K 2-O-beta-D-glucopyranoside|Cucurbitacin K 2-O-??-glucopyranoside

2-O-beta-D-glucopyranosylcucurbitacin K,J|cucurbitacin J 2-O-beta-D-glucopyranoside|cucurbitacin J 2-O-beta-glucopyranoside|cucurbitacin K 2-O-beta-D-glucopyranoside|Cucurbitacin K 2-O-??-glucopyranoside

C36H54O13 (694.3564)


   

thevetioside D

thevetioside D

C36H54O13 (694.3564)


   

Glycocinnasperimicin D

Glycocinnasperimicin D

C30H50N10O9 (694.3762)


   

2alpha,3beta,19alpha-trihydroxyurs-12-en-24,28-dioic acid-28-O-(6-O-methyl-beta-D-glucopyranosyl) ester

2alpha,3beta,19alpha-trihydroxyurs-12-en-24,28-dioic acid-28-O-(6-O-methyl-beta-D-glucopyranosyl) ester

C37H58O12 (694.3928)


   

(25S)-ruscogenin 1-O-beta-D-xylopyranosyl-(1->3)-alpha-L-arabinopyranoside|angudracanoside F

(25S)-ruscogenin 1-O-beta-D-xylopyranosyl-(1->3)-alpha-L-arabinopyranoside|angudracanoside F

C37H58O12 (694.3928)


   

C36H54O13_Card-20(22)-enolide, 3-[(2,6-dideoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-xylo-hexopyranosyl)oxy]-14-hydroxy-19-oxo-, (3beta,5alpha,17alpha)

NCGC00385325-01_C36H54O13_Card-20(22)-enolide, 3-[(2,6-dideoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-xylo-hexopyranosyl)oxy]-14-hydroxy-19-oxo-, (3beta,5alpha,17alpha)-

C36H54O13 (694.3564)


   

FRLFL

Phe-Arg-Leu-Phe-Leu

C36H54N8O6 (694.4166)


   

LERMF

Leu-Glu-Arg-Met-Phe

C31H50N8O8S (694.3472)


   

PFYLR

Pro Phe Tyr Leu Arg

C35H50N8O7 (694.3802)


   

LDYRE

Leu Asp Tyr Arg Glu

C30H46N8O11 (694.3286)


   

Capsoside A

2-[(3E)-hex-3-enoyloxy]-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl dodecanoate

C33H58O15 (694.3776)


   

PHODA-PG

1-hexadecanoyl-2-(9-hydroxy-12-oxo-10E-dodecenoyl)-sn-glycero-3-phospho-(1-sn-glycerol)

C34H63O12P (694.4057)


   

4-Ketonostoxanthin 3-sulfate

4-Ketonostoxanthin 3-sulfate

C40H54O8S (694.3539)


   

Bastaxanthin D

(3R,1R,3R,5R)-19,3,17-trihydroxy-6-oxo-7,8-didehydro-beta,kappa-caroten-3-yl sulphate

C40H54O8S (694.3539)


   
   

H-DL-Phe(4-F)-DL-xiHyp-DL-Arg-Gly-DL-Trp-NH2

H-DL-Phe(4-F)-DL-xiHyp-DL-Arg-Gly-DL-Trp-NH2

C33H43FN10O6 (694.3351)


   

PA(13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C38H63O9P (694.4209)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/13:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/13:0)

C38H63O9P (694.4209)


   

PA(13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C38H63O9P (694.4209)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/13:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/13:0)

C38H63O9P (694.4209)


   

PA(13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C38H63O9P (694.4209)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/13:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/13:0)

C38H63O9P (694.4209)


   

PA(13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C38H63O9P (694.4209)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/13:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/13:0)

C38H63O9P (694.4209)


   

PA(13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C38H63O9P (694.4209)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/13:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/13:0)

C38H63O9P (694.4209)


   

PA(a-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(a-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C38H63O9P (694.4209)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/a-13:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/a-13:0)

C38H63O9P (694.4209)


   

PA(a-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(a-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C38H63O9P (694.4209)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/a-13:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/a-13:0)

C38H63O9P (694.4209)


   

PA(a-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(a-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C38H63O9P (694.4209)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/a-13:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/a-13:0)

C38H63O9P (694.4209)


   

PA(a-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(a-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C38H63O9P (694.4209)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/a-13:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/a-13:0)

C38H63O9P (694.4209)


   

PA(a-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(a-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C38H63O9P (694.4209)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/a-13:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/a-13:0)

C38H63O9P (694.4209)


   

PA(i-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(i-13:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C38H63O9P (694.4209)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-13:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/i-13:0)

C38H63O9P (694.4209)


   

PA(i-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(i-13:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C38H63O9P (694.4209)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-13:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/i-13:0)

C38H63O9P (694.4209)


   

PA(i-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(i-13:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C38H63O9P (694.4209)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-13:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/i-13:0)

C38H63O9P (694.4209)


   

PA(i-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(i-13:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C38H63O9P (694.4209)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-13:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/i-13:0)

C38H63O9P (694.4209)


   

PA(i-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(i-13:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C38H63O9P (694.4209)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-13:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/i-13:0)

C38H63O9P (694.4209)


   

cucurbitacin J 2-O-beta-D-glucopyranoside

cucurbitacin J 2-O-beta-D-glucopyranoside

C36H54O13 (694.3564)


A triterpenoid saponin that is the beta-D-glucopyranosyl derivative of cucurbitacin J. It has been isolated from Machilus yaoshansis.

   

cucurbitacin K 2-O-beta-D-glucopyranoside

cucurbitacin K 2-O-beta-D-glucopyranoside

C36H54O13 (694.3564)


A triterpenoid saponin of the type of cucurbitane glycosides isolated from Machilus yaoshansis.

   

2,2-{Propane-1,3-diylbis[(dimethylazaniumdiyl)propane-3,1-diylpyridin-1-yl-4-ylidenemethylylidene]}bis(3-methyl-1,3-benzothiazol-3-ium)

2,2-{Propane-1,3-diylbis[(dimethylazaniumdiyl)propane-3,1-diylpyridin-1-yl-4-ylidenemethylylidene]}bis(3-methyl-1,3-benzothiazol-3-ium)

C41H54N6S2+4 (694.3851)


   

Smgdg O-17:2_8:0

Smgdg O-17:2_8:0

C34H62O12S (694.3962)


   

Smgdg O-19:2_6:0

Smgdg O-19:2_6:0

C34H62O12S (694.3962)


   

Smgdg O-16:2_9:0

Smgdg O-16:2_9:0

C34H62O12S (694.3962)


   

Smgdg O-20:2_5:0

Smgdg O-20:2_5:0

C34H62O12S (694.3962)


   

Smgdg O-22:2_3:0

Smgdg O-22:2_3:0

C34H62O12S (694.3962)


   

Smgdg O-8:0_17:2

Smgdg O-8:0_17:2

C34H62O12S (694.3962)


   

Smgdg O-21:2_4:0

Smgdg O-21:2_4:0

C34H62O12S (694.3962)


   

Smgdg O-18:2_7:0

Smgdg O-18:2_7:0

C34H62O12S (694.3962)


   

Smgdg O-9:0_16:2

Smgdg O-9:0_16:2

C34H62O12S (694.3962)


   

Dgdg O-17:1_2:0

Dgdg O-17:1_2:0

C34H62O14 (694.4139)


   

Dgdg O-16:1_3:0

Dgdg O-16:1_3:0

C34H62O14 (694.4139)


   

Dgdg O-15:1_4:0

Dgdg O-15:1_4:0

C34H62O14 (694.4139)


   

Dgdg O-13:1_6:0

Dgdg O-13:1_6:0

C34H62O14 (694.4139)


   

Dgdg O-14:1_5:0

Dgdg O-14:1_5:0

C34H62O14 (694.4139)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C38H63O9P (694.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C38H63O9P (694.4209)


   

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-tridec-9-enoate

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-tridec-9-enoate

C33H58O15 (694.3776)


   

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-hexadec-9-enoate

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-hexadec-9-enoate

C33H58O15 (694.3776)


   

[1-butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-tetradec-9-enoate

[1-butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-tetradec-9-enoate

C33H58O15 (694.3776)


   

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-pentadec-9-enoate

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-pentadec-9-enoate

C33H58O15 (694.3776)


   

[6-[3-dodecanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[6-[3-dodecanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C34H62O12S (694.3962)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C33H59O13P (694.3693)


   

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C33H59O13P (694.3693)


   

[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C33H59O13P (694.3693)


   

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C33H59O13P (694.3693)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C33H59O13P (694.3693)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C33H59O13P (694.3693)


   

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

C33H59O13P (694.3693)


   

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C34H62O12S (694.3962)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C37H59O10P (694.3846)


   

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(E)-tetradec-9-enoyl]oxy-3-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(E)-tetradec-9-enoyl]oxy-3-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C34H62O12S (694.3962)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C37H59O10P (694.3846)


   

[(2R,3R,6R)-6-[(2S)-2-decanoyloxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2R,3R,6R)-6-[(2S)-2-decanoyloxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C34H62O12S (694.3962)


   

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-[(E)-tetradec-9-enoyl]oxy-2-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-[(E)-tetradec-9-enoyl]oxy-2-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C34H62O12S (694.3962)


   

phosphatidylserine 30:6(1-)

phosphatidylserine 30:6(1-)

C36H57NO10P (694.372)


A 3-sn-phosphatidyl-L-serine(1-) in which the acyl groups at C-1 and C-2 contain 30 carbons in total and 6 double bonds.

   
   
   
   
   
   
   

PA 14:1/20:6;O2

PA 14:1/20:6;O2

C37H59O10P (694.3846)


   

PA 22:4/12:3;O2

PA 22:4/12:3;O2

C37H59O10P (694.3846)


   

PA 22:5/11:3;O3

PA 22:5/11:3;O3

C36H55O11P (694.3482)


   

PA 22:5/12:2;O2

PA 22:5/12:2;O2

C37H59O10P (694.3846)


   
   
   
   

PG O-16:0/12:3;O3

PG O-16:0/12:3;O3

C34H63O12P (694.4057)


   

PG O-16:3/16:4

PG O-16:3/16:4

C38H63O9P (694.4209)


   

PG O-20:0/8:3;O3

PG O-20:0/8:3;O3

C34H63O12P (694.4057)


   
   

PG P-16:0/12:2;O3

PG P-16:0/12:2;O3

C34H63O12P (694.4057)


   

PG P-20:0/8:2;O3

PG P-20:0/8:2;O3

C34H63O12P (694.4057)


   

PG 16:0/11:3;O3

PG 16:0/11:3;O3

C33H59O13P (694.3693)


   

PG 16:0/12:2;O2

PG 16:0/12:2;O2

C34H63O12P (694.4057)


   
   
   
   
   
   
   
   
   
   

PI O-16:0/8:3;O

PI O-16:0/8:3;O

C33H59O13P (694.3693)


   
   
   

PI P-16:0/7:3;O2

PI P-16:0/7:3;O2

C32H55O14P (694.3329)


   

PI P-16:1/7:2;O2

PI P-16:1/7:2;O2

C32H55O14P (694.3329)


   

PI P-16:1/8:1;O

PI P-16:1/8:1;O

C33H59O13P (694.3693)


   

PI P-18:0/6:2;O

PI P-18:0/6:2;O

C33H59O13P (694.3693)


   

PI P-18:1/5:2;O2

PI P-18:1/5:2;O2

C32H55O14P (694.3329)


   

PI P-20:1/4:1;O

PI P-20:1/4:1;O

C33H59O13P (694.3693)


   
   
   
   
   
   
   
   
   
   

(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a-hydroxy-7-{[(2r,4r,5s,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O13 (694.3564)


   

4-methyl 8a-(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylate

4-methyl 8a-(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylate

C37H58O12 (694.3928)


   

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(5r,6s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(5r,6s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O9 (694.4081)


   

(1r,2r,3ar,5s,9s,10s,11s,13r,13ar)-9,10,11-tris(acetyloxy)-1,3a-dihydroxy-2,5,8,8-tetramethyl-13-{[(2r)-2-methylbutanoyl]oxy}-12-methylidene-4-oxo-1h,3h,5h,9h,10h,11h,13h,13ah-cyclopenta[12]annulen-2-yl (2r)-2-methylbutanoate

(1r,2r,3ar,5s,9s,10s,11s,13r,13ar)-9,10,11-tris(acetyloxy)-1,3a-dihydroxy-2,5,8,8-tetramethyl-13-{[(2r)-2-methylbutanoyl]oxy}-12-methylidene-4-oxo-1h,3h,5h,9h,10h,11h,13h,13ah-cyclopenta[12]annulen-2-yl (2r)-2-methylbutanoate

C36H54O13 (694.3564)


   

(2r,3r,4s,5s,6r)-2-{[(2s,4as,6r,8as)-8a-methyl-4-methylidene-6-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydronaphthalen-2-yl]oxy}-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(2s,4as,6r,8as)-8a-methyl-4-methylidene-6-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydronaphthalen-2-yl]oxy}-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

C32H54O16 (694.3412)


   

(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5s,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5s,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O13 (694.3564)


   

5-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,3r,4s,5r,6s)-3,4-dihydroxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]pyran-2-one

5-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,3r,4s,5r,6s)-3,4-dihydroxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]pyran-2-one

C36H54O13 (694.3564)


   

(4s,4as,5r,6s,8ar,9as)-9a-[(4s,4as,5r,6s,8ar,9as)-6-hydroxy-3,4a,5-trimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-6-hydroxy-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-4-yl (2z)-2-methylbut-2-enoate

(4s,4as,5r,6s,8ar,9as)-9a-[(4s,4as,5r,6s,8ar,9as)-6-hydroxy-3,4a,5-trimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-6-hydroxy-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-4-yl (2z)-2-methylbut-2-enoate

C40H54O10 (694.3717)


   

(2r,3r,4r,5r,7s,8s,9s,11e,13s,15r)-2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one-7,8,9-triacetate-2,5-bis(2-methylbuty-rate)

NA

C36H54O13 (694.3564)


{"Ingredient_id": "HBIN006417","Ingredient_name": "(2r,3r,4r,5r,7s,8s,9s,11e,13s,15r)-2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one-7,8,9-triacetate-2,5-bis(2-methylbuty-rate)","Alias": "NA","Ingredient_formula": "C36H54O13","Ingredient_Smile": "CCC(C)C(=O)OC1C2C(C(CC2(C(=O)C(C=CC(C(C(C(C1=C)OC(=O)C)OC(=O)C)OC(=O)C)(C)C)C)O)(C)OC(=O)C(C)CC)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9397","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

atractyloside e

NA

C32H54O16 (694.3412)


{"Ingredient_id": "HBIN017305","Ingredient_name": "atractyloside e","Alias": "NA","Ingredient_formula": "C32H54O16","Ingredient_Smile": "CC12CCC(CC1C(=C)CC(C2)OC3C(C(C(C(O3)COC4C(C(CO4)(CO)O)O)O)O)O)C(C)(C)OC5C(C(C(C(O5)CO)O)O)O","Ingredient_weight": "694.8 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14422","TCMID_id": "1978","TCMSP_id": "NA","TCM_ID_id": "6489","PubChem_id": "101831403","DrugBank_id": "NA"}

   

4-[(3s,4ar,6ar,6bs,9s,10ar,11as,11bs)-6b-hydroxy-3-{[(2r,3r,4s,5s,6s)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11b-methyl-10-methylidene-tetradecahydrocyclohexa[a]fluoren-9-yl]-5h-furan-2-one

4-[(3s,4ar,6ar,6bs,9s,10ar,11as,11bs)-6b-hydroxy-3-{[(2r,3r,4s,5s,6s)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11b-methyl-10-methylidene-tetradecahydrocyclohexa[a]fluoren-9-yl]-5h-furan-2-one

C36H54O13 (694.3564)


   

2-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl)cyclohexa-2,5-diene-1,4-dione

2-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl)cyclohexa-2,5-diene-1,4-dione

C44H54O7 (694.3869)


   

(1s,3br,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

(1s,3br,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O9 (694.4081)


   

(2z,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5z)-6-methyl-7-[(3-methylbutanoyl)oxy]hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl 3-methylbutanoate

(2z,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5z)-6-methyl-7-[(3-methylbutanoyl)oxy]hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl 3-methylbutanoate

C40H54O10 (694.3717)


   

8a-({[3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy}carbonyl)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

8a-({[3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy}carbonyl)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C37H58O12 (694.3928)


   

4-[(3s,4ar,6ar,6bs,9s,10ar,11as,11bs)-6b-hydroxy-3-{[(2r,3s,4s,5s,6s)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11b-methyl-10-methylidene-tetradecahydrocyclohexa[a]fluoren-9-yl]-5h-furan-2-one

4-[(3s,4ar,6ar,6bs,9s,10ar,11as,11bs)-6b-hydroxy-3-{[(2r,3s,4s,5s,6s)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11b-methyl-10-methylidene-tetradecahydrocyclohexa[a]fluoren-9-yl]-5h-furan-2-one

C36H54O13 (694.3564)


   

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3r,5r,6s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3r,5r,6s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O9 (694.4081)


   

4-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl]cyclohexa-3,5-diene-1,2-dione

4-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl]cyclohexa-3,5-diene-1,2-dione

C44H54O7 (694.3869)


   

2-{[8a-methyl-4-methylidene-6-(2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydronaphthalen-2-yl]oxy}-6-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

2-{[8a-methyl-4-methylidene-6-(2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydronaphthalen-2-yl]oxy}-6-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

C32H54O16 (694.3412)


   

(1r,2r,3as,3bs,9ar,9br,11ar)-2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,5r)-2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl]-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

(1r,2r,3as,3bs,9ar,9br,11ar)-2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,5r)-2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl]-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H54O13 (694.3564)


   

(2s,4ar,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-11-hydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(2s,4ar,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-11-hydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O12 (694.3928)


   

11-hydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

11-hydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O12 (694.3928)


   

4-{6b-hydroxy-3-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11b-methyl-10-methylidene-tetradecahydrocyclohexa[a]fluoren-9-yl}-5h-furan-2-one

4-{6b-hydroxy-3-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11b-methyl-10-methylidene-tetradecahydrocyclohexa[a]fluoren-9-yl}-5h-furan-2-one

C36H54O13 (694.3564)


   

4-{3a-hydroxy-7-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

4-{3a-hydroxy-7-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

C36H54O13 (694.3564)


   

4,9-bis(acetyloxy)-1-[5-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

4,9-bis(acetyloxy)-1-[5-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O9 (694.4081)


   

2-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-4-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl]cyclohexa-2,5-diene-1,4-dione

2-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-4-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl]cyclohexa-2,5-diene-1,4-dione

C44H54O7 (694.3869)


   

{14-ethyl-4,6,19,21-tetramethoxy-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-16-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

{14-ethyl-4,6,19,21-tetramethoxy-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-16-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C38H50N2O10 (694.3465)


   

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C37H58O12 (694.3928)


   

(2z,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5z)-6-methyl-7-{[(2r)-2-methylbutanoyl]oxy}hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl (2s)-2-methylbutanoate

(2z,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5z)-6-methyl-7-{[(2r)-2-methylbutanoyl]oxy}hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl (2s)-2-methylbutanoate

C40H54O10 (694.3717)


   

2-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl]cyclohexa-2,5-diene-1,4-dione

2-{3-[(4e)-6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl]cyclohexa-2,5-diene-1,4-dione

C44H54O7 (694.3869)


   

6-(4,4'-dihydroxy-2',6-dimethyl-5'-{6-methyl-7-[(3-methylbutanoyl)oxy]hept-5-en-2-yl}-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl)-2-methylhept-2-en-1-yl 3-methylbutanoate

6-(4,4'-dihydroxy-2',6-dimethyl-5'-{6-methyl-7-[(3-methylbutanoyl)oxy]hept-5-en-2-yl}-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl)-2-methylhept-2-en-1-yl 3-methylbutanoate

C40H54O10 (694.3717)


   

(2r,6s,7s,8r,10s,11s,12r,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(2r,6s,7s,8r,10s,11s,12r,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C39H50O11 (694.3353)


   

4-methyl 8a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylate

4-methyl 8a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylate

C37H58O12 (694.3928)


   

(4s,4as,5r,6s,8as,9as)-9a-[(4s,4as,5r,6s,8as,9as)-6-hydroxy-3,4a,5-trimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-6-hydroxy-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-4-yl (2z)-2-methylbut-2-enoate

(4s,4as,5r,6s,8as,9as)-9a-[(4s,4as,5r,6s,8as,9as)-6-hydroxy-3,4a,5-trimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-6-hydroxy-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-4-yl (2z)-2-methylbut-2-enoate

C40H54O10 (694.3717)


   

(1r,2r,3as,3bs,4s,9ar,9bs,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,4-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

(1r,2r,3as,3bs,4s,9ar,9bs,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,4-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H54O13 (694.3564)


   

(2z,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5z)-6-methyl-7-{[(2r)-2-methylbutanoyl]oxy}hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl (2r)-2-methylbutanoate

(2z,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5z)-6-methyl-7-{[(2r)-2-methylbutanoyl]oxy}hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl (2r)-2-methylbutanoate

C40H54O10 (694.3717)


   

6-hydroxy-9a-{6-hydroxy-3,4a,5-trimethyl-4-[(2-methylbut-2-enoyl)oxy]-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl}-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-4-yl 2-methylbut-2-enoate

6-hydroxy-9a-{6-hydroxy-3,4a,5-trimethyl-4-[(2-methylbut-2-enoyl)oxy]-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl}-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-4-yl 2-methylbut-2-enoate

C40H54O10 (694.3717)


   

(6s,6ar,10as,14r)-12-hexanoyl-7,10a,13-trihydroxy-6-isopropyl-2,2,4,4,8,8,10,10-octamethyl-14-(2-methylpropyl)-6,6a,7,14-tetrahydro-5,11-dioxapentaphene-1,3,9-trione

(6s,6ar,10as,14r)-12-hexanoyl-7,10a,13-trihydroxy-6-isopropyl-2,2,4,4,8,8,10,10-octamethyl-14-(2-methylpropyl)-6,6a,7,14-tetrahydro-5,11-dioxapentaphene-1,3,9-trione

C41H58O9 (694.4081)


   

11-hydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

11-hydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O12 (694.3928)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,5r,8r,9r,10s,11r,13r,14r,15r,17s,18s)-11,17-dihydroxy-8-(2-methoxy-2-oxoethyl)-1,2,6,6,9-pentamethyl-15-(prop-1-en-2-yl)-7-oxapentacyclo[11.7.0.0²,¹⁰.0⁵,⁹.0¹⁴,¹⁸]icosane-18-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,5r,8r,9r,10s,11r,13r,14r,15r,17s,18s)-11,17-dihydroxy-8-(2-methoxy-2-oxoethyl)-1,2,6,6,9-pentamethyl-15-(prop-1-en-2-yl)-7-oxapentacyclo[11.7.0.0²,¹⁰.0⁵,⁹.0¹⁴,¹⁸]icosane-18-carboxylate

C37H58O12 (694.3928)


   

10-(acetyloxy)-3-(1-bromo-2-hydroxyethyl)-5-hydroxy-3,11a-dimethyl-7-methylidene-2h,4h,4ah,5h,6h,6ah,8h,9h,10h,11h-cyclohepta[a]naphthalen-9-yl hexadecanoate

10-(acetyloxy)-3-(1-bromo-2-hydroxyethyl)-5-hydroxy-3,11a-dimethyl-7-methylidene-2h,4h,4ah,5h,6h,6ah,8h,9h,10h,11h-cyclohepta[a]naphthalen-9-yl hexadecanoate

C38H63BrO6 (694.3808)


   

(2s,3r,4s,5r)-2-{[(2s,3r,4s,5s)-3,5-dihydroxy-2-[(1's,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,14'r,16'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-4-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5r)-2-{[(2s,3r,4s,5s)-3,5-dihydroxy-2-[(1's,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,14'r,16'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-4-yl]oxy}oxane-3,4,5-triol

C37H58O12 (694.3928)


   

(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2s,3r,4s,5r)-5-{[(2s,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-3,4-dihydroxyoxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2s,3r,4s,5r)-5-{[(2s,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-3,4-dihydroxyoxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C36H54O13 (694.3564)


   

1-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,4-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

1-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,4-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H54O13 (694.3564)


   

4-[(1r,4s,6s,9r,10r,13r,14r)-4-hydroxy-6-{[(2r,4s,5s,6r)-4-(hydroxymethyl)-6-methyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9,13-dimethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl]-5h-furan-2-one

4-[(1r,4s,6s,9r,10r,13r,14r)-4-hydroxy-6-{[(2r,4s,5s,6r)-4-(hydroxymethyl)-6-methyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9,13-dimethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl]-5h-furan-2-one

C36H54O13 (694.3564)


   

(2s)-2-[(3z)-hex-3-enoyloxy]-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl dodecanoate

(2s)-2-[(3z)-hex-3-enoyloxy]-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl dodecanoate

C33H58O15 (694.3776)


   

(1r,2r,6s,7r,8r,10s,11r,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(1r,2r,6s,7r,8r,10s,11r,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C39H50O11 (694.3353)


   

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s,5r,6s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s,5r,6s)-5,6-dihydroxy-7,7-dimethyloxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O9 (694.4081)


   

4,9-bis(acetyloxy)-1-(5,6-dihydroxy-7,7-dimethyloxepan-3-yl)-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

4,9-bis(acetyloxy)-1-(5,6-dihydroxy-7,7-dimethyloxepan-3-yl)-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O9 (694.4081)


   

(2s,3r,4s,5r)-2-[2-(6-chlorododecyl)-5-(6,6-dichlorotridecyl)-3-hydroxyphenoxy]oxane-3,4,5-triol

(2s,3r,4s,5r)-2-[2-(6-chlorododecyl)-5-(6,6-dichlorotridecyl)-3-hydroxyphenoxy]oxane-3,4,5-triol

C36H61Cl3O6 (694.3533)


   

(2s,3r,4s,5r)-2-{[(2s,3r,4s,5s)-3,5-dihydroxy-2-[(1's,2r,2's,5s,7's,8'r,9's,12's,13'r,14'r,16'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-4-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5r)-2-{[(2s,3r,4s,5s)-3,5-dihydroxy-2-[(1's,2r,2's,5s,7's,8'r,9's,12's,13'r,14'r,16'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-4-yl]oxy}oxane-3,4,5-triol

C37H58O12 (694.3928)


   

(2e)-n-{3-[(4-aminobutyl)amino]propyl}-3-{4-[(3-carbamimidamido-5-{n-[4,5-dihydroxy-3-(c-hydroxycarbonimidoylamino)oxan-2-yl]-(c-hydroxycarbonimidoyl)amino}-4-hydroxy-6-methyloxan-2-yl)oxy]phenyl}prop-2-enimidic acid

(2e)-n-{3-[(4-aminobutyl)amino]propyl}-3-{4-[(3-carbamimidamido-5-{n-[4,5-dihydroxy-3-(c-hydroxycarbonimidoylamino)oxan-2-yl]-(c-hydroxycarbonimidoyl)amino}-4-hydroxy-6-methyloxan-2-yl)oxy]phenyl}prop-2-enimidic acid

C30H50N10O9 (694.3762)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2s,3r,4r)-4-methyl-5-oxo-2-[(14s)-14-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]oxolane-3-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2s,3r,4r)-4-methyl-5-oxo-2-[(14s)-14-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]oxolane-3-carboxylate

C33H58O15 (694.3776)


   

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s,5r,6r)-5-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s,5r,6r)-5-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H58O9 (694.4081)


   

3a-hydroxy-7-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

3a-hydroxy-7-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde

C36H54O13 (694.3564)


   

(1r,2r,3as,3bs,9ar,9br,11ar)-2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,5s)-2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl]-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

(1r,2r,3as,3bs,9ar,9br,11ar)-2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,5s)-2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl]-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H54O13 (694.3564)


   

(1r,2r,3as,3bs,4s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,4-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

(1r,2r,3as,3bs,4s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,4-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H54O13 (694.3564)


   

[(1s,2r,3r,4s,5r,6s,8r,12s,13s,16s,19s,20r,21s)-14-ethyl-4,6,19,21-tetramethoxy-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-16-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

[(1s,2r,3r,4s,5r,6s,8r,12s,13s,16s,19s,20r,21s)-14-ethyl-4,6,19,21-tetramethoxy-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-16-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C38H50N2O10 (694.3465)


   

4-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl)cyclohexa-3,5-diene-1,2-dione

4-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-5-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl)cyclohexa-3,5-diene-1,2-dione

C44H54O7 (694.3869)


   

(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-8a-({[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy}carbonyl)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-8a-({[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy}carbonyl)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C37H58O12 (694.3928)


   

2-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-4-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl)cyclohexa-2,5-diene-1,4-dione

2-{3-[6-(2,6-dihydroxy-4-methylphenyl)-4-methylhex-4-en-1-yl]-4-(2-methylprop-1-en-1-yl)furan-2-yl}-5-hydroxy-3-methyl-6-(3,7,11-trimethyl-9-oxododeca-2,6,10-trien-1-yl)cyclohexa-2,5-diene-1,4-dione

C44H54O7 (694.3869)


   

4-[(3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5s,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5s,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C36H54O13 (694.3564)


   

5-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]pyran-2-one

5-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]pyran-2-one

C36H54O13 (694.3564)


   

(2e,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5e)-6-methyl-7-[(3-methylbutanoyl)oxy]hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl 3-methylbutanoate

(2e,6s)-6-{4,4'-dihydroxy-2',6-dimethyl-5'-[(2s,5e)-6-methyl-7-[(3-methylbutanoyl)oxy]hept-5-en-2-yl]-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl}-2-methylhept-2-en-1-yl 3-methylbutanoate

C40H54O10 (694.3717)


   

7-({5-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-3,4-dihydroxyoxan-2-yl}oxy)-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

7-({5-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-3,4-dihydroxyoxan-2-yl}oxy)-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C36H54O13 (694.3564)


   

2-[(3,5-dihydroxy-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy}oxan-4-yl)oxy]oxane-3,4,5-triol

2-[(3,5-dihydroxy-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy}oxan-4-yl)oxy]oxane-3,4,5-triol

C37H58O12 (694.3928)


   

5-{7-[(3,4-dihydroxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}pyran-2-one

5-{7-[(3,4-dihydroxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-3a-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}pyran-2-one

C36H54O13 (694.3564)


   

6-(4,4'-dihydroxy-2',6-dimethyl-5'-{6-methyl-7-[(2-methylbutanoyl)oxy]hept-5-en-2-yl}-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl)-2-methylhept-2-en-1-yl 2-methylbutanoate

6-(4,4'-dihydroxy-2',6-dimethyl-5'-{6-methyl-7-[(2-methylbutanoyl)oxy]hept-5-en-2-yl}-2,3',5,6'-tetraoxo-[1,1'-bi(cyclohexane)]-1(6),1',3,4'-tetraen-3-yl)-2-methylhept-2-en-1-yl 2-methylbutanoate

C40H54O10 (694.3717)


   

(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C37H58O12 (694.3928)


   

2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-(2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl)-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

2-hydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-(2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl)-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H54O13 (694.3564)


   

[(1r,6r)-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4s,5r)-4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-6-hydroxy-3,5,5-trimethylcyclohex-3-en-1-yl]oxidanesulfonic acid

[(1r,6r)-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4s,5r)-4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-6-hydroxy-3,5,5-trimethylcyclohex-3-en-1-yl]oxidanesulfonic acid

C40H54O8S (694.3539)


   

(1r,2r,5z,10r,11r)-3,18-dihydroxy-5,16-bis({[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene})-4,7,14,17-tetraazapentacyclo[9.7.0.0¹,¹⁴.0²,⁷.0²,¹⁰]octadeca-3,17-diene-6,15-dione

(1r,2r,5z,10r,11r)-3,18-dihydroxy-5,16-bis({[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene})-4,7,14,17-tetraazapentacyclo[9.7.0.0¹,¹⁴.0²,⁷.0²,¹⁰]octadeca-3,17-diene-6,15-dione

C42H42N6O4 (694.3267)


   

(3s,6r,9r,10r,12s)-6-benzyl-3-[(2s)-butan-2-yl]-8,10-dihydroxy-4,9-dimethyl-12-[(2s,7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

(3s,6r,9r,10r,12s)-6-benzyl-3-[(2s)-butan-2-yl]-8,10-dihydroxy-4,9-dimethyl-12-[(2s,7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

C36H58N2O11 (694.404)


   

9,10,11-tris(acetyloxy)-1,3a-dihydroxy-2,5,8,8-tetramethyl-13-[(2-methylbutanoyl)oxy]-12-methylidene-4-oxo-1h,3h,5h,9h,10h,11h,13h,13ah-cyclopenta[12]annulen-2-yl 2-methylbutanoate

9,10,11-tris(acetyloxy)-1,3a-dihydroxy-2,5,8,8-tetramethyl-13-[(2-methylbutanoyl)oxy]-12-methylidene-4-oxo-1h,3h,5h,9h,10h,11h,13h,13ah-cyclopenta[12]annulen-2-yl 2-methylbutanoate

C36H54O13 (694.3564)


   

(2r,3r,4s,5s,6r)-2-{[(2s,4as,6r,8ar)-8a-methyl-4-methylidene-6-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydronaphthalen-2-yl]oxy}-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(2s,4as,6r,8ar)-8a-methyl-4-methylidene-6-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydronaphthalen-2-yl]oxy}-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

C32H54O16 (694.3412)


   

4-[(1r,4s,6s,9r,13r,14r)-4-hydroxy-6-{[(2r,4s,5s,6r)-4-(hydroxymethyl)-6-methyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9,13-dimethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl]-5h-furan-2-one

4-[(1r,4s,6s,9r,13r,14r)-4-hydroxy-6-{[(2r,4s,5s,6r)-4-(hydroxymethyl)-6-methyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9,13-dimethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl]-5h-furan-2-one

C36H54O13 (694.3564)


   

(1s,2s,5z,10s,11s)-3,18-dihydroxy-5,16-bis({[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene})-4,7,14,17-tetraazapentacyclo[9.7.0.0¹,¹⁴.0²,⁷.0²,¹⁰]octadeca-3,17-diene-6,15-dione

(1s,2s,5z,10s,11s)-3,18-dihydroxy-5,16-bis({[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene})-4,7,14,17-tetraazapentacyclo[9.7.0.0¹,¹⁴.0²,⁷.0²,¹⁰]octadeca-3,17-diene-6,15-dione

C42H42N6O4 (694.3267)


   

(3s,4ar,5r,6ar,9r,10r,11ar)-10-(acetyloxy)-3-[(1r)-1-bromo-2-hydroxyethyl]-5-hydroxy-3,11a-dimethyl-7-methylidene-2h,4h,4ah,5h,6h,6ah,8h,9h,10h,11h-cyclohepta[a]naphthalen-9-yl hexadecanoate

(3s,4ar,5r,6ar,9r,10r,11ar)-10-(acetyloxy)-3-[(1r)-1-bromo-2-hydroxyethyl]-5-hydroxy-3,11a-dimethyl-7-methylidene-2h,4h,4ah,5h,6h,6ah,8h,9h,10h,11h-cyclohepta[a]naphthalen-9-yl hexadecanoate

C38H63BrO6 (694.3808)


   

2-(hex-3-enoyloxy)-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl dodecanoate

2-(hex-3-enoyloxy)-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl dodecanoate

C33H58O15 (694.3776)


   

4-[(3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5r,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5r,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C36H54O13 (694.3564)


   

(3s,6r,9r,10r,12s)-6-benzyl-8,10-dihydroxy-4,9-dimethyl-3-(2-methylpropyl)-12-[(2s,7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

(3s,6r,9r,10r,12s)-6-benzyl-8,10-dihydroxy-4,9-dimethyl-3-(2-methylpropyl)-12-[(2s,7r)-7-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octan-2-yl]-1-oxa-4,7-diazacyclododec-7-ene-2,5-dione

C36H58N2O11 (694.404)